Post-Acute Withdrawal Syndrome: Recognizing Protracted Symptoms in Practice

Post-acute withdrawal syndrome (PAWS) describes a constellation of neuropsychiatric, somatic, and autonomic symptoms that persist or emerge weeks to months after acute discontinuation of a CNS-active drug has resolved. Despite being absent from DSM-5-TR and ICD-11 as a discrete entity, PAWS is recognized in the addiction medicine literature, the Maudsley Deprescribing Guidelines (Horowitz & Taylor, 2024), and a growing body of pharmacovigilance data. The clinical problem for prescribers is twofold: distinguishing protracted withdrawal from relapse of the original disorder, and resisting the reflexive reinstatement of the offending agent when symptoms are, in fact, pharmacologically driven and time-limited.

Definition and pharmacological rationale

The acute withdrawal phase typically resolves within 4–6 weeks for short-half-life agents and longer for agents with active metabolites or depot pharmacokinetics. PAWS is operationally defined as withdrawal-attributable symptoms persisting beyond this acute window — commonly 6 weeks to 24 months, with a long tail in a subset of patients.

The mechanistic substrate is incomplete neuroadaptive reversal. Chronic exposure to agonists, antagonists, or reuptake inhibitors produces homeostatic changes in receptor density, intracellular signaling cascades, and downstream gene expression. Examples relevant to deprescribing:

• SSRIs/SNRIs — downregulation of postsynaptic 5-HT1A receptors and altered serotonin transporter function. Receptor occupancy data (Sørensen et al., 2022, Lancet Psychiatry) show hyperbolic dose-response curves: occupancy remains high until very low doses, so symptoms can emerge late in the taper or after the final dose.
• Benzodiazepines — GABA-A receptor subunit reconfiguration and reduced GABAergic tone with reciprocal glutamatergic upregulation. The Ashton Manual (Ashton, 2002) describes protracted symptoms persisting 6–18 months in a subset of long-term users.
• Antipsychotics — dopamine receptor supersensitivity (D2 upregulation) and cholinergic/histaminergic rebound, particularly after agents with high anticholinergic load (clozapine, olanzapine, quetiapine).
• Opioids — sustained dysregulation of the locus coeruleus noradrenergic system and HPA axis abnormalities lasting months.
• Gabapentinoids — calcium channel α2δ subunit changes producing sensory disturbance and dysautonomia.

The unifying feature is that receptor and network homeostasis recovers on a slower timescale than drug elimination. A 5-day washout does not equal full neurochemical normalization.

Symptom domains

PAWS presentations cluster across four domains. A given patient may have features from one, two, or all four.

| Domain | Common features | || | Affective | Anhedonia, emotional blunting, dysphoria, anxiety surges, mood lability, suicidality without prior history | | Cognitive | Brain fog, impaired concentration, derealization, depersonalization, intrusive thoughts | | Somatic/sensory | Tinnitus, paresthesias, "brain zaps," visual snow, photophobia, headache, myalgia, GI dysmotility | | Autonomic/sleep | Insomnia, vivid dreams, night sweats, postural intolerance, temperature dysregulation, palpitations |

Brain zaps (electrical-shock sensations triggered by lateral eye movement) are nearly pathognomonic of serotonergic discontinuation and are reported in 30–80% of SSRI/SNRI discontinuation cohorts depending on agent and methodology (Fava et al., 2015, Psychotherapy and Psychosomatics).

Differential diagnosis: relapse, withdrawal, or emergent disorder

The single most consequential clinical task is differentiating these three possibilities. Misclassification has direct treatment implications: relapse warrants reinstatement at therapeutic dose; withdrawal warrants reinstatement at the last tolerated dose followed by slower hyperbolic taper; an emergent disorder warrants targeted treatment of that disorder.

Features favoring withdrawal/PAWS over relapse

1. Symptom novelty. Symptoms not present in the original disorder (e.g., brain zaps, akathisia, derealization in a patient whose original presentation was unipolar depression without anxiety) strongly suggest withdrawal.
2. Temporal pattern. Onset within hours to weeks of dose reduction or discontinuation. Relapse of major depressive disorder typically requires weeks to months to redevelop the full syndrome; SSRI discontinuation symptoms often emerge within 24–72 hours for short-half-life agents (paroxetine, venlafaxine).
3. Wave-and-window pattern. PAWS classically fluctuates: symptom-free windows of hours or days alternate with symptomatic waves. A linearly worsening course is more typical of relapse.
4. Response to reinstatement. Withdrawal symptoms typically resolve within hours to days of reinstating the prior dose. Depressive relapse takes 2–6 weeks to respond to pharmacotherapy.
5. Symptom phenomenology. Sensory phenomena (zaps, tinnitus, visual disturbance), gait disturbance, dysautonomia, and akathisia are withdrawal features. Pure anhedonia, hopelessness, and psychomotor slowing without somatic features are more consistent with depressive relapse.

Emergent disorder considerations

A subset of patients develop genuine new pathology during taper. Examples include:

• Tardive dysphoria or tardive akathisia after long-term antipsychotic exposure.
• Persistent sexual dysfunction after SSRI discontinuation (PSSD), now described in EMA pharmacovigilance data (2019) and FDA Adverse Event Reporting System reports.
• Persistent genital arousal disorder (PGAD) post-SSRI.
• Protracted insomnia after long-term Z-drug or benzodiazepine use, with documented changes in sleep architecture lasting beyond 12 months.

These are not strictly "withdrawal" — they are persistent iatrogenic conditions. Reinstatement is generally not curative.

Drug-specific PAWS profiles

SSRIs and SNRIs

Discontinuation symptoms are well-characterized for paroxetine (t½ ≈ 21 h, no active metabolite — highest withdrawal risk), venlafaxine (t½ ≈ 5 h for parent, 11 h for ODV), and duloxetine. Fluoxetine (t½ 1–4 days, norfluoxetine 7–15 days) has the lowest acute discontinuation burden but can still produce PAWS in long-term users.

Davies and Read (2019, Addictive Behaviors) systematically reviewed 14 studies and reported a withdrawal incidence of 56% (range 27–86%), with approximately 46% of those affected describing severity as severe. Duration data are heterogeneous, but a meaningful subset reports symptoms beyond 6 months — particularly with paroxetine, venlafaxine, and after rapid or "linear" tapers.

Hyperbolic tapering, recommended in the Maudsley Deprescribing Guidelines, addresses the receptor occupancy curve. For example, halving the dose of citalopram from 20 mg to 10 mg reduces SERT occupancy from approximately 80% to 70%; halving again to 5 mg drops occupancy to roughly 60%; the largest occupancy change occurs from 5 mg to 0 mg. This explains why patients tolerate the high end of the taper and crash at the bottom.

Benzodiazepines

The Ashton Manual remains the most cited clinical reference. Protracted symptoms include anxiety, perceptual disturbance (tinnitus, formication), motor symptoms (tremor, fasciculations), and cognitive dysfunction. Symptoms may persist 6–18 months and, in a small subset, longer. Reinstatement at the last tolerated dose with substitution to a long-half-life agent (typically diazepam) followed by slow micro-titrated taper is the standard approach for severe protracted cases.

Antipsychotics

Dopamine supersensitivity psychosis (Chouinard et al., 2017, Psychotherapy and Psychosomatics) is the most consequential PAWS-equivalent for antipsychotics, characterized by emergent psychosis or rapid relapse on dose reduction in patients previously stable. Cholinergic rebound after abrupt discontinuation of high-anticholinergic agents (clozapine, olanzapine, quetiapine) produces nausea, diaphoresis, insomnia, and agitation lasting weeks. Tardive dyskinesia and tardive akathisia may unmask or worsen on taper.

Opioids

Acute opioid withdrawal resolves in 7–10 days. Protracted withdrawal includes dysphoria, anhedonia, anxiety, insomnia, and cold intolerance lasting 2–6 months, with HPA axis dysregulation documented for up to 12 months in heavy users. This is one of the most robustly characterized PAWS phenotypes in the addiction literature.

Gabapentinoids

Gabapentin and pregabalin produce a distinct discontinuation syndrome with sensory disturbance, anxiety surges, and dysautonomia. Reports of protracted symptoms beyond 6 weeks are accumulating in pharmacovigilance data.

Risk factors for protracted course

Empirical predictors of more severe and prolonged PAWS:

• Duration of exposure beyond 2–5 years of continuous use.
• Higher cumulative dose and use at the upper end of the licensed range.
• Short-half-life agent with no active metabolite (paroxetine, venlafaxine, alprazolam, lorazepam).
• Rapid or linear taper (e.g., halving every 2 weeks).
• Prior failed taper attempt with reinstatement.
• Polypharmacy with multiple CNS-active agents tapered concurrently.
• High pre-taper anxiety sensitivity or prior history of withdrawal.

Assessment in clinic

A structured visit minimizes diagnostic error. Suggested elements:

1. Symptom diary review. Ask the patient to log symptoms hourly or daily for 2 weeks. The wave-and-window pattern is diagnostic if present.
2. Discontinuation Emergent Signs and Symptoms (DESS) scale — a 43-item checklist validated for SSRI discontinuation. Useful for tracking trajectory across visits.
3. Pre-taper symptom baseline. Compare current symptoms to the original presentation. Novel symptoms are not relapse.
4. Timeline reconstruction. Map dose changes against symptom onset. A clear temporal yoking favors withdrawal.
5. Rule out medical mimics. Hyperthyroidism, vestibular dysfunction, vitamin B12 deficiency, postural orthostatic tachycardia syndrome, and inner ear pathology can mimic PAWS features.
6. Suicide risk assessment. PAWS-associated suicidality, particularly with akathisia, requires explicit assessment regardless of premorbid risk.

Management

The core principles are pharmacological stability, symptomatic support, and time.

Pharmacological stabilization

If PAWS emerges during an active taper, the first decision is whether to reinstate. Reinstatement is most reliably effective when initiated within 4–6 weeks of the precipitating dose change. After this window, reinstatement may produce paradoxical worsening or no benefit, particularly with serotonergic agents.

If reinstating, return to the last tolerated dose, not the original therapeutic dose. Once stabilized for 4–8 weeks, resume tapering at a slower pace, using compounded liquid, custom-compounded capsules, or scored tablets to enable small decrements. The Maudsley guidelines provide hyperbolic taper tables for major agents and remain the most practical reference at the bedside.

If symptoms emerged after full discontinuation and weeks have passed, reinstatement is a clinical judgment call. Some patients benefit from low-dose reinstatement followed by slow taper; others worsen. Discuss the uncertainty explicitly with the patient before any trial.

Symptomatic support

Targeted, time-limited symptomatic treatment is appropriate while the underlying neuroadaptation resolves:

• Insomnia — sleep hygiene, CBT-I, low-dose melatonin, time-limited trazodone (avoid Z-drugs and benzodiazepines if the index drug was sedative-hypnotic).
• Akathisia — propranolol 10–40 mg three times daily, or short course of clonidine. Avoid antipsychotics in serotonergic withdrawal akathisia.
• Autonomic instability — propranolol, hydration, salt loading if orthostatic.
• Brain zaps — generally self-limited; magnesium and omega-3 fatty acids have anecdotal support without controlled data.
• GI symptoms — ondansetron for nausea; loperamide for diarrhea (caution with opioid history).

Non-pharmacological support

Sleep regularity, aerobic exercise titrated to tolerance (overexertion can trigger waves), structured daily activity, and cognitive-behavioral support targeting catastrophic interpretation of symptoms. Patients catastrophizing each wave as relapse experience worse functional outcomes than those framing waves as expected pharmacological events.

Communicating with patients

The clinician's framing shapes outcome. Suggested language adaptable to the encounter:

• "These symptoms are a recognized consequence of the brain reversing the changes the medication produced. They are time-limited in most people, though the timeline is longer than the package insert suggests."
• "Expect a wave-and-window pattern. A bad day does not mean the process has failed."
• "If reinstatement is needed, the goal is stability so the taper can resume more slowly — not a return to chronic treatment."
• "These symptoms will not be interpreted as a return of the original condition unless the original pattern reappears."

Avoid both dismissal ("the drug is out of your system, this can't be withdrawal") and catastrophizing ("you may never recover"). Both worsen outcomes.

Documentation and pharmacovigilance

PAWS underrecognition is partly a documentation problem. Submit MedWatch (FDA), Yellow Card (UK MHRA), or equivalent reports for protracted symptoms beyond 6 weeks. Aggregate pharmacovigilance data (RxISK, EudraVigilance) is what eventually shifts label warnings — as it did for paroxetine and venlafaxine.

Clinical pearls

• Novel symptoms after dose reduction are not relapse until proven otherwise. Brain zaps, akathisia, derealization, and dysautonomia are withdrawal features regardless of the original diagnosis.
• The wave-and-window pattern is diagnostically useful. A two-week symptom diary often resolves the relapse-versus-withdrawal question without further investigation.
• Reinstate to the last tolerated dose, not the original therapeutic dose. Then resume a slower hyperbolic taper using compounded liquid or precision formulations.
• Hyperbolic, not linear, tapers match receptor occupancy biology. The largest pharmacodynamic change occurs at the bottom of the dose range.
• Treat symptoms, not the syndrome. Propranolol for akathisia, sleep interventions for insomnia, time for sensory phenomena. Avoid layering new CNS-active agents.
• Document and report. Pharmacovigilance reporting for protracted withdrawal is how labeling and clinical norms eventually change.

---

For more clinician resources on safe deprescribing and tapering, visit tapermeds.com.